5 completed, 2 recruiting, 1 terminated. 6 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 4, Recruiting 2 |
| Phase 4 | 1 | Terminated 1 |
Follow Panzyga: new trials by email Literature Review of Panzyga trials Research Report on Panzyga
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections Panzyga, 10% Intravenous Solution, Placebo - Hypogammaglobulinemia, Autoimmune Conditions | Phase 3 | Recruiting | Octapharma | 360 | 2026-06-10 | 2026-09-29 |
| Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients Panzyga - Pediatric Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Recruiting | Octapharma | 30 | 2023-10-01 | 2026-08-05 |
| Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS) Panzyga, Placebo - Pediatric Acute-Onset Neuropsychiatric Syndrome | Phase 3 | Completed | Octapharma | 71 | 2021-06-30 | 2026-01-07 |
| Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) Panzyga, Placebo - Chronic Lymphocytic Leukemia, Hypogammaglobulinemia | Phase 3 | Completed | Octapharma | 247 | 2020-10-05 | 2026-06-04 |
| Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) Panzyga - Chronic Immune Thrombocytopenia | Phase 4 | Terminated | Octapharma | 6 | 2020-01-21 | 2024-09-24 |
| Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy NewGam - Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy | Phase 3 | Completed | Octapharma | 142 | 2017-09-27 | 2021-02-16 |
| Non-Interventional Study on the Tolerability and Efficacy of IVIG Octagam IVIG 5% or 10%, Panzyga - Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG | Completed | Octapharma | 344 | 2011-08-01 | 2021-06-29 | |
| Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma Clinical Observation, Cyclophosphamide, Laboratory Biomarker Analysis - Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma | Phase 3 | Completed | Children's Oncology Group | 53 | 2004-03-15 | 2023-04-18 |
Agammaglobulinemia (2) · Infections (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Neuroblastoma (1) · Pediatric acute-onset neuropsychiatric syndrome (1)
Octapharma (7) · Children's Oncology Group (1)
United States (6) · Canada (3) · Poland (3) · Bulgaria (2) · Czechia (2) · Germany (2) · Greece (2) · Hungary (2) · Italy (2) · Russia (2) · Spain (2) · Australia (1) · Austria (1) · Denmark (1) · France (1)
Lidia Cosentino (1) · Pedro A De Alarcon (1) · Wolfgang Frenzel, MD (1)
PMID 29376112, PMID 35038723, PMID 37378806, PMID 38353301
U10CA013539 (1), U10CA098543 (1), U10CA180886 (1)